Skip to main content

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Poster Presentations for Upcoming SfN Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience (“SfN”) Conference. The event is slated to take place from Nov. 12-16, 2022, in San Diego. “We are excited our collaborators at the University of Michigan are presenting the results of our two recent studies. The first study explored intravenous psilocybin and its effect in a recognized rat model of fibromyalgia. This model exhibits increased sensitivity to touch and hypersensitivity to elevated temperatures. Administration of a single intravenous infusion of psilocybin resulted in a decrease in both pain and heat sensitivity persisting until the end of the study (28 days). Tryp is the first company to pursue the use of psychedelics in nociplastic pain indications including fibromyalgia. These results support the potential clinical utility of psilocybin assisted therapy in the treatment of patients with fibromyalgia,” said Tryp’s CEO Jim Gilligan. “The second study demonstrated a change in EEG recordings coincident with achieving the psychedelic state. Rats received a continuous intravenous infusion of psilocybin over a period of 60 minutes while EEG data were simultaneously monitored. The results demonstrate the ability to detect changes in EEG patterns coincident with attaining the psychedelic state. In addition, upon cessation of the infusion a return to baseline EEG patterns correlated with decreasing blood levels of psilocin. This study will help facilitate Tryp’s program to utilize EEG recordings to optimize dose and infusion rates of TRP-8803 (IV psilocin) in planned upcoming clinical trials.”

To view the full press release, visit

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.